▲▲▲▲▲ ///////////////////////////////////////////////// ········ ··
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
━━━━━━━━━━
NSG 552
PSYCHOPHARMACOLOGY
EXAM 3
2026/2027 EDITION
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
━━━━━━━━━━
150 Real Exam Questions & Answers with Detailed Rationales
Already Graded A+ | 100% Verified Authentic Content
Target Credential: Psychiatric-Mental Health Nurse Course & Scope: NSG 552 Advanced
Practitioner (PMHNP-BC) Psychopharmacology (Comprehensive Exam 3)
Edition & Guidelines: 2026/2027 Master Curriculum Question Count: 150 Verified High-Yield Multi-
| FDA & APA Practice Standards Choice Questions & Scenarios
·········· ·········· ◆ ◆ ◆ [ NSG 552 | 2026-2027 ] ◆ ◆ ◆
,Section 1: Brief Introduction
This master examination document comprises 150 authentic, high-yield examination questions
designed for advanced practice registered nursing and PMHNP students preparing for the NSG 552
Psychopharmacology Exam 3. Comprehensive coverage integrates evidence-based
neuropsychopharmacology, receptor signal transduction, CYP450 pharmacokinetics,
pharmacogenomic testing, pharmacotherapy across psychiatric disorders, adverse effect
mitigation, and special population prescribing reflecting 2025–2026 FDA and APA clinical
guidelines. Each self-contained question incorporates randomized four-option multiple-choice
formatting with verified bold cyan answer selections and detailed mechanistic rationales.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
━━━━━━━━━━━━━━━━━━━━━━
Section 2: The Complete Exam
Question 1. A 42-year-old male with treatment-resistant depression is stabilized on clozapine and
fluvoxamine. After abruptly stopping his two-pack-per-day cigarette habit upon admission to a
smoke-free facility, he develops severe sedation, ataxia, and excessive sialorrhea. Which
cytochrome P450 (CYP) pharmacokinetic interaction explains this toxicity?
A. Tobacco smoke induces hepatic CYP3A4, so abrupt cessation increases clozapine
glucuronidation and active metabolite formation.
B. Polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2; smoking
cessation eliminates this induction, causing clozapine serum levels to rise significantly.
C. Nicotine directly inhibits CYP2D6, and cessation accelerates clozapine clearance through
secondary hepatic pathways.
D. Cigarette smoke inhibits CYP2C19, and cessation enhances the protein-binding
displacement of clozapine by fluvoxamine.
Rationale: Polycyclic aromatic hydrocarbons in tobacco smoke (not nicotine itself) are potent inducers
of CYP1A2. When a heavy smoker abruptly discontinues smoking, CYP1A2 activity decreases back to
baseline, reducing clozapine metabolism and causing serum clozapine levels to increase by up to 50–
100%, precipitating toxicity.
Question 2. A PMHNP reviews pharmacogenomic testing for a 28-year-old Asian female prior to
initiating carbamazepine for bipolar I disorder. Testing reveals she is positive for the HLA-B*1502
allele. What is the most appropriate clinical action?
A. Pre-treat with oral prednisone for 14 days prior to slowly titrating carbamazepine to
therapeutic levels.
B. Avoid carbamazepine and oxcarbazepine due to a high risk of Stevens-Johnson
syndrome (SJS) and toxic epidermal necrolysis (TEN).
, C. Switch to lamotrigine at standard rapid titration because HLA-B*1502 confers cross-
reactivity exclusively with valproate.
D. Initiate carbamazepine at one-fourth the standard dose with weekly serum drug
concentration monitoring.
Rationale: The FDA black box warning mandates testing for the HLA-B*1502 allele in patients of Asian
descent prior to carbamazepine initiation. Patients positive for HLA-B*1502 are at high risk for life-
threatening cutaneous adverse reactions (SJS/TEN) and should not be prescribed carbamazepine or
oxcarbazepine unless the benefit clearly outweighs the risk.
Question 3. A 34-year-old female taking paroxetine 40 mg daily for generalized anxiety disorder is
prescribed tamoxifen for estrogen receptor-positive breast cancer. Why should the PMHNP switch
the patient from paroxetine to an alternative anxiolytic such as venlafaxine or escitalopram?
A. Paroxetine stimulates estrogen receptors directly, counteracting the competitive
antagonism of tamoxifen.
B. Paroxetine induces CYP3A4, accelerating tamoxifen clearance and causing premature drug
toxicity.
C. Tamoxifen displaces paroxetine from plasma albumin, causing severe serotonin syndrome
and hypertensive crisis.
D. Paroxetine is a potent CYP2D6 inhibitor that blocks the bioactivation of tamoxifen
into its active anti-cancer metabolite, endoxifen.
Rationale: Tamoxifen is a prodrug requiring metabolic activation by CYP2D6 into its active oncolytic
metabolite, endoxifen. Strong CYP2D6 inhibitors like paroxetine and fluoxetine substantially reduce
endoxifen concentrations, leading to increased breast cancer recurrence and mortality; venlafaxine or
escitalopram are preferred due to minimal CYP2D6 inhibition.
Question 4. According to receptor binding profiles and signal transduction principles, what
distinguishes a 'partial agonist' (such as aripiprazole) from a 'full agonist' and an 'antagonist' at the
dopamine D2 receptor?
A. A partial agonist produces maximal biological efficacy but possesses lower receptor
binding affinity than endogenous dopamine.
B. A partial agonist binds irreversibly to allosteric sites, permanently downregulating
downstream cyclic AMP synthesis regardless of endogenous ligand levels.
C. A partial agonist stabilizes the receptor in an inactive constitutive conformation,
completely suppressing basal G-protein coupling.
D. A partial agonist binds to the receptor and produces an intrinsic submaximal
biological response, acting as a functional antagonist in hyperdopaminergic states and a
functional agonist in hypodopaminergic states.
Rationale: A partial agonist exhibits intrinsic efficacy intermediate between a full agonist (100%
efficacy) and a silent antagonist (0% efficacy). In brain regions with high endogenous dopamine
, (mesolimbic pathway), it competes for D2 receptors and lowers dopamine signaling, while in low-
dopamine environments (mesocortical pathway), it boosts intrinsic dopamine receptor signaling.
Question 5. Pharmacogenetic testing reveals that a 45-year-old male with major depressive
disorder is a CYP2D6 'poor metabolizer' (*4/*4 genotype). Which of the following prescribing
decisions is most appropriate?
A. Increase the starting dose of venlafaxine to bypass deficient hepatic first-pass activation.
B. Reduce the initial dosage of atomoxetine, aripiprazole, or venlafaxine by
approximately 50% due to reduced drug clearance and elevated plasma levels.
C. Avoid all SSRIs because poor metabolizers cannot convert parent SSRI molecules into
active compounds.
D. Prescribe duloxetine at double the maximum recommended dose to compensate for rapid
Phase II glucuronidation.
Rationale: CYP2D6 poor metabolizers lack functional CYP2D6 enzyme activity, leading to substantially
elevated plasma concentrations and prolonged half-lives of substrates like atomoxetine, aripiprazole,
and venlafaxine. Clinical guidelines recommend initiating substrates at 50% of the standard dose or
selecting agents metabolized via alternative pathways.
Question 6. A 52-year-old female taking a stable dose of simvastatin is started on fluvoxamine for
obsessive-compulsive disorder. Within three weeks, she reports severe muscle pain, dark urine,
and weakness, with a serum creatine kinase (CK) of 12,000 U/L. What mechanism caused this drug-
drug interaction?
A. Fluvoxamine induces CYP2C9, leading to toxic accumulation of active hydroxylated statin
metabolites.
B. Fluvoxamine is a potent inhibitor of CYP3A4 and CYP1A2, which blocks simvastatin
hepatic metabolism and dramatically increases systemic statin levels, triggering
rhabdomyolysis.
C. Fluvoxamine displaces simvastatin from renal tubular organic anion transporters,
inhibiting urinary filtration.
D. Fluvoxamine causes direct skeletal muscle cell lysis through uncoupling of mitochondrial
oxidative phosphorylation.
Rationale: Fluvoxamine is a potent inhibitor of both CYP1A2 and CYP3A4. Simvastatin is extensively
metabolized by CYP3A4; concurrent administration with potent CYP3A4 inhibitors causes marked
increases in simvastatin bioavailability and plasma concentrations, dramatically elevating the risk of
statin-induced myopathy and life-threatening rhabdomyolysis.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
━━━━━━━━━━
NSG 552
PSYCHOPHARMACOLOGY
EXAM 3
2026/2027 EDITION
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
━━━━━━━━━━
150 Real Exam Questions & Answers with Detailed Rationales
Already Graded A+ | 100% Verified Authentic Content
Target Credential: Psychiatric-Mental Health Nurse Course & Scope: NSG 552 Advanced
Practitioner (PMHNP-BC) Psychopharmacology (Comprehensive Exam 3)
Edition & Guidelines: 2026/2027 Master Curriculum Question Count: 150 Verified High-Yield Multi-
| FDA & APA Practice Standards Choice Questions & Scenarios
·········· ·········· ◆ ◆ ◆ [ NSG 552 | 2026-2027 ] ◆ ◆ ◆
,Section 1: Brief Introduction
This master examination document comprises 150 authentic, high-yield examination questions
designed for advanced practice registered nursing and PMHNP students preparing for the NSG 552
Psychopharmacology Exam 3. Comprehensive coverage integrates evidence-based
neuropsychopharmacology, receptor signal transduction, CYP450 pharmacokinetics,
pharmacogenomic testing, pharmacotherapy across psychiatric disorders, adverse effect
mitigation, and special population prescribing reflecting 2025–2026 FDA and APA clinical
guidelines. Each self-contained question incorporates randomized four-option multiple-choice
formatting with verified bold cyan answer selections and detailed mechanistic rationales.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
━━━━━━━━━━━━━━━━━━━━━━
Section 2: The Complete Exam
Question 1. A 42-year-old male with treatment-resistant depression is stabilized on clozapine and
fluvoxamine. After abruptly stopping his two-pack-per-day cigarette habit upon admission to a
smoke-free facility, he develops severe sedation, ataxia, and excessive sialorrhea. Which
cytochrome P450 (CYP) pharmacokinetic interaction explains this toxicity?
A. Tobacco smoke induces hepatic CYP3A4, so abrupt cessation increases clozapine
glucuronidation and active metabolite formation.
B. Polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2; smoking
cessation eliminates this induction, causing clozapine serum levels to rise significantly.
C. Nicotine directly inhibits CYP2D6, and cessation accelerates clozapine clearance through
secondary hepatic pathways.
D. Cigarette smoke inhibits CYP2C19, and cessation enhances the protein-binding
displacement of clozapine by fluvoxamine.
Rationale: Polycyclic aromatic hydrocarbons in tobacco smoke (not nicotine itself) are potent inducers
of CYP1A2. When a heavy smoker abruptly discontinues smoking, CYP1A2 activity decreases back to
baseline, reducing clozapine metabolism and causing serum clozapine levels to increase by up to 50–
100%, precipitating toxicity.
Question 2. A PMHNP reviews pharmacogenomic testing for a 28-year-old Asian female prior to
initiating carbamazepine for bipolar I disorder. Testing reveals she is positive for the HLA-B*1502
allele. What is the most appropriate clinical action?
A. Pre-treat with oral prednisone for 14 days prior to slowly titrating carbamazepine to
therapeutic levels.
B. Avoid carbamazepine and oxcarbazepine due to a high risk of Stevens-Johnson
syndrome (SJS) and toxic epidermal necrolysis (TEN).
, C. Switch to lamotrigine at standard rapid titration because HLA-B*1502 confers cross-
reactivity exclusively with valproate.
D. Initiate carbamazepine at one-fourth the standard dose with weekly serum drug
concentration monitoring.
Rationale: The FDA black box warning mandates testing for the HLA-B*1502 allele in patients of Asian
descent prior to carbamazepine initiation. Patients positive for HLA-B*1502 are at high risk for life-
threatening cutaneous adverse reactions (SJS/TEN) and should not be prescribed carbamazepine or
oxcarbazepine unless the benefit clearly outweighs the risk.
Question 3. A 34-year-old female taking paroxetine 40 mg daily for generalized anxiety disorder is
prescribed tamoxifen for estrogen receptor-positive breast cancer. Why should the PMHNP switch
the patient from paroxetine to an alternative anxiolytic such as venlafaxine or escitalopram?
A. Paroxetine stimulates estrogen receptors directly, counteracting the competitive
antagonism of tamoxifen.
B. Paroxetine induces CYP3A4, accelerating tamoxifen clearance and causing premature drug
toxicity.
C. Tamoxifen displaces paroxetine from plasma albumin, causing severe serotonin syndrome
and hypertensive crisis.
D. Paroxetine is a potent CYP2D6 inhibitor that blocks the bioactivation of tamoxifen
into its active anti-cancer metabolite, endoxifen.
Rationale: Tamoxifen is a prodrug requiring metabolic activation by CYP2D6 into its active oncolytic
metabolite, endoxifen. Strong CYP2D6 inhibitors like paroxetine and fluoxetine substantially reduce
endoxifen concentrations, leading to increased breast cancer recurrence and mortality; venlafaxine or
escitalopram are preferred due to minimal CYP2D6 inhibition.
Question 4. According to receptor binding profiles and signal transduction principles, what
distinguishes a 'partial agonist' (such as aripiprazole) from a 'full agonist' and an 'antagonist' at the
dopamine D2 receptor?
A. A partial agonist produces maximal biological efficacy but possesses lower receptor
binding affinity than endogenous dopamine.
B. A partial agonist binds irreversibly to allosteric sites, permanently downregulating
downstream cyclic AMP synthesis regardless of endogenous ligand levels.
C. A partial agonist stabilizes the receptor in an inactive constitutive conformation,
completely suppressing basal G-protein coupling.
D. A partial agonist binds to the receptor and produces an intrinsic submaximal
biological response, acting as a functional antagonist in hyperdopaminergic states and a
functional agonist in hypodopaminergic states.
Rationale: A partial agonist exhibits intrinsic efficacy intermediate between a full agonist (100%
efficacy) and a silent antagonist (0% efficacy). In brain regions with high endogenous dopamine
, (mesolimbic pathway), it competes for D2 receptors and lowers dopamine signaling, while in low-
dopamine environments (mesocortical pathway), it boosts intrinsic dopamine receptor signaling.
Question 5. Pharmacogenetic testing reveals that a 45-year-old male with major depressive
disorder is a CYP2D6 'poor metabolizer' (*4/*4 genotype). Which of the following prescribing
decisions is most appropriate?
A. Increase the starting dose of venlafaxine to bypass deficient hepatic first-pass activation.
B. Reduce the initial dosage of atomoxetine, aripiprazole, or venlafaxine by
approximately 50% due to reduced drug clearance and elevated plasma levels.
C. Avoid all SSRIs because poor metabolizers cannot convert parent SSRI molecules into
active compounds.
D. Prescribe duloxetine at double the maximum recommended dose to compensate for rapid
Phase II glucuronidation.
Rationale: CYP2D6 poor metabolizers lack functional CYP2D6 enzyme activity, leading to substantially
elevated plasma concentrations and prolonged half-lives of substrates like atomoxetine, aripiprazole,
and venlafaxine. Clinical guidelines recommend initiating substrates at 50% of the standard dose or
selecting agents metabolized via alternative pathways.
Question 6. A 52-year-old female taking a stable dose of simvastatin is started on fluvoxamine for
obsessive-compulsive disorder. Within three weeks, she reports severe muscle pain, dark urine,
and weakness, with a serum creatine kinase (CK) of 12,000 U/L. What mechanism caused this drug-
drug interaction?
A. Fluvoxamine induces CYP2C9, leading to toxic accumulation of active hydroxylated statin
metabolites.
B. Fluvoxamine is a potent inhibitor of CYP3A4 and CYP1A2, which blocks simvastatin
hepatic metabolism and dramatically increases systemic statin levels, triggering
rhabdomyolysis.
C. Fluvoxamine displaces simvastatin from renal tubular organic anion transporters,
inhibiting urinary filtration.
D. Fluvoxamine causes direct skeletal muscle cell lysis through uncoupling of mitochondrial
oxidative phosphorylation.
Rationale: Fluvoxamine is a potent inhibitor of both CYP1A2 and CYP3A4. Simvastatin is extensively
metabolized by CYP3A4; concurrent administration with potent CYP3A4 inhibitors causes marked
increases in simvastatin bioavailability and plasma concentrations, dramatically elevating the risk of
statin-induced myopathy and life-threatening rhabdomyolysis.
